deltatrials
Terminated PHASE2 NCT00818090

Paclitaxel and Cisplatin for Thymic Neoplasm

A Phase II Study of Paclitaxel and Cisplatin in Previously Untreated, Unresectable Invasive Thymoma or Thymic Carcinoma

Sponsor: Korean Cancer Study Group

Conditions Thymic Carcinoma Thymoma
Interventions paclitaxel and cisplatin
Updated 6 times since 2017 Last updated: Apr 11, 2013 Started: Sep 30, 2008 Primary completion: Nov 30, 2011 Completion: Nov 30, 2011

Listed as NCT00818090, this PHASE2 trial focuses on Thymic Carcinoma and Thymoma and remains terminated or withdrawn. Sponsored by Korean Cancer Study Group, it has been updated 6 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Korean Cancer Study Group
Data source: Korean Cancer Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Seoul, South Korea